

## ASX Announcement

### Investor Webinar -- Final HER-Vaxx Overall Survival Results

---

**Sydney, Australia, 27 June 2022:** Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, is pleased to announce it will hold an investor webinar today, **Monday 27 June 2022 at 11am AEST** with Managing Director/CEO Leslie Chong, who will be joined by Principal Investigator of the study Dr Tanuj Chawla and consulting statistician Brent Blumenstein.

They will discuss today's announcement regarding the final HER-Vaxx overall survival results in a randomized Phase 2 trial in advanced gastric cancer, as well as taking questions from attendees.

Please register for the webinar at the following link: [https://us02web.zoom.us/webinar/register/WN\\_LikeBynRCCJ3iIUK-JFvg](https://us02web.zoom.us/webinar/register/WN_LikeBynRCCJ3iIUK-JFvg)

Investors are encouraged to send questions prior to the webinar to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

After registering, you will receive a confirmation email about joining the webinar. A recording will be available at the same link shortly after the conclusion of the session.

For more information please contact:

**Leslie Chong**  
**Managing Director and Chief Executive Officer**  
[info@imugene.com](mailto:info@imugene.com)

**Investor Enquiries**  
[investor@imugene.com](mailto:investor@imugene.com)

**Media Enquiries**  
Matt Wright  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Follow us on Twitter @TeamImugene  
Like us on Facebook @Imugene  
Connect with us on LinkedIn @Imugene Limited

### About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate



tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immunology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer  
Imugene Limited, Level 3, 62 Lygon Street, Carlton, VIC, 3053, Australia*